Updates are available Correction dated 2023-12-05
Click to view Correction: https://doi.org/10.1007/s41669-023-00462-7
-
Authors
Chaplin, Marty https://orcid.org/0000-0002-7097-8704
Bresnahan, Rebecca https://orcid.org/0000-0001-5578-1535
Fleeman, Nigel https://orcid.org/0000-0002-4637-9779
Mahon, James https://orcid.org/0000-0002-2187-1003
Houten, Rachel https://orcid.org/0000-0002-4315-7732
Beale, Sophie https://orcid.org/0000-0003-0164-103X
Boland, Angela https://orcid.org/0000-0002-5435-8644
Dundar, Yenal https://orcid.org/0000-0002-9847-1622
Marsden, Ashley
Munot, Pinki https://orcid.org/0000-0001-9900-798X
-
Funding
Funding for this research was provided by:
Evidence Synthesis Programme (NIHR135653)
- License Information
-
More Information
Article History
Accepted: 3 September 2023
First Online: 20 September 2023
Change Date: 5 December 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s41669-023-00462-7
Declarations
:
: This project was funded by the National Institute for Health Research Evidence Synthesis Programme as project number NIHR135653 (see the Evidence Synthesis Programme website for further project information – . The views and opinions expressed herein are those of the authors and do not necessarily reflect those of the NICE or the Department of Health.
: Marty Chaplin, Rebecca Bresnahan, Nigel Fleeman, James Mahon, Rachel Houten, Sophie Beale, Angela Boland, Yenal Dundar, Ashley Marsden and Pinki Munot have no conflicts of interest to declare.
: Not applicable.
: Not applicable.
: Not applicable.
: MC: Critical appraisal of the clinical and statistical evidence, drafted versions of the paper. RB: Project lead, critical appraisal of the clinical evidence and supervised the final report. NF: Critical appraisal of the clinical evidence. JM: Critical appraisal of the economic model. RH: Critical appraisal of the economic model. SB: Critical appraisal of the clinical and economic evidence, editorial input. AB: Critical appraisal of the clinical and economic evidence, editorial input. YD: Critical appraisal of the company’s search strategies. AM: Critical appraisal of the company submission, PM: Clinical advice and critical appraisal of the clinical evidence.
: Not applicable.
: Not applicable.
